ASB Consultores LLC Sells 468 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

ASB Consultores LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 37.2% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 790 shares of the pharmaceutical company’s stock after selling 468 shares during the period. ASB Consultores LLC’s holdings in Vertex Pharmaceuticals were worth $370,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Capital World Investors lifted its stake in shares of Vertex Pharmaceuticals by 17.2% in the 1st quarter. Capital World Investors now owns 25,567,184 shares of the pharmaceutical company’s stock worth $10,687,339,000 after purchasing an additional 3,761,414 shares during the period. Vanguard Group Inc. lifted its stake in shares of Vertex Pharmaceuticals by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 22,676,518 shares of the pharmaceutical company’s stock worth $9,479,011,000 after purchasing an additional 394,338 shares during the period. Capital Research Global Investors lifted its stake in shares of Vertex Pharmaceuticals by 61.0% in the 1st quarter. Capital Research Global Investors now owns 5,743,882 shares of the pharmaceutical company’s stock worth $2,401,000,000 after purchasing an additional 2,176,218 shares during the period. Jennison Associates LLC lifted its stake in shares of Vertex Pharmaceuticals by 21.2% in the 1st quarter. Jennison Associates LLC now owns 4,782,374 shares of the pharmaceutical company’s stock worth $1,999,080,000 after purchasing an additional 837,461 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Vertex Pharmaceuticals by 10.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,584,315 shares of the pharmaceutical company’s stock worth $1,080,296,000 after acquiring an additional 244,336 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.8 %

NASDAQ VRTX opened at $477.90 on Friday. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average of $483.14 and a two-hundred day moving average of $451.58. The firm has a market capitalization of $123.32 billion, a price-to-earnings ratio of 31.01 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.85 and a 52 week high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.66 billion. During the same period in the previous year, the firm earned $3.53 earnings per share. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on VRTX. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, August 2nd. Truist Financial restated a “buy” rating and set a $550.00 target price (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research note on Monday, August 5th. Guggenheim raised their target price on shares of Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Oppenheimer raised their target price on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $486.36.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares in the company, valued at $2,217,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $487.34, for a total value of $1,111,135.20. Following the completion of the sale, the chief marketing officer now directly owns 27,819 shares in the company, valued at $13,557,311.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,047 shares of company stock worth $16,843,806. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.